Alejandro Parrales相关文献与解析，生知库

Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin

天然化合物白花丹素衍生的 HSP40/J 结构域蛋白的新型抑制剂可消除突变型 p53

Mohamed Alalem, Mrinalini Bhosale, Atul Ranjan, Satomi Yamamoto, Atsushi Kaida, Shigeto Nishikawa, Alejandro Parrales, Sana Farooki, Shrikant Anant, Subhash Padhye, Tomoo Iwakuma

信号转导

Human

发表日期：2022

文献求助收藏

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

突变型p53抑制先天免疫信号传导，从而促进肿瘤发生

期刊:Cancer Cell

影响因子:48.8

doi:10.1016/j.ccell.2021.01.003

Monisankar Ghosh ，Suchandrima Saha ，Julie Bettke ，Rachana Nagar ，Alejandro Parrales ，Tomoo Iwakuma ，Adrianus W M van der Velden ，Luis A Martinez

Comparative oncology approach to drug repurposing in osteosarcoma

骨肉瘤药物再利用的比较肿瘤学方法

期刊:PLoS One

影响因子:2.9

doi:10.1371/journal.pone.0194224

Alejandro Parrales, Peter McDonald, Megan Ottomeyer, Anuradha Roy, Frank J Shoenen, Melinda Broward, Tyce Bruns, Douglas H Thamm, Scott J Weir, Kathleen A Neville, Tomoo Iwakuma, Joy M Fulbright1

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

DNAJA1 通过甲羟戊酸途径控制错误折叠突变 p53 的命运

期刊:Nature Cell Biology

影响因子:17.3

doi:10.1038/ncb3427

Alejandro Parrales, Atul Ranjan, Swathi V Iyer, Subhash Padhye, Scott J Weir, Anuradha Roy, Tomoo Iwakuma

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression

全基因组 RNAi 筛选确定 TMIGD3 同工酶 1 是 NF-κB 和骨肉瘤进展的抑制因子

期刊:Nature Communications

影响因子:14.7

doi:10.1038/ncomms13561

Swathi V Iyer, Atul Ranjan, Harold K Elias, Alejandro Parrales, Hiromi Sasaki, Badal C Roy, Shahid Umar, Ossama W Tawfik, Tomoo Iwakuma

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

突变型 p53 的等位基因特异性沉默可减弱显性负性和功能获得性活性

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.6634

Swathi V Iyer, Alejandro Parrales, Priya Begani, Akshay Narkar, Amit S Adhikari, Luis A Martinez, Tomoo Iwakuma

发表日期：2016

文献求助收藏

Targeting Oncogenic Mutant p53 for Cancer Therapy

针对致癌突变 p53 进行癌症治疗

期刊:Frontiers in Oncology

影响因子:3.5

doi:10.3389/fonc.2015.00288

Alejandro Parrales, Tomoo Iwakuma

肿瘤

发表日期：2015

文献求助收藏

Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways

凝血酶通过激活汇聚信号通路促进RPE细胞Ccnd1基因表达

期刊:Experimental Eye Research

影响因子:3

doi:10.1016/j.exer.2015.08.001

Irene Lee-Rivera, Edith López, Alejandro Parrales, Alejandro Alvarez-Arce, Ana María López-Colomé

Suppression of stress granule formation is a vulnerability imposed by mutant p53

突变型p53导致应激颗粒形成受到抑制，这是一种脆弱性。

Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin

天然化合物白花丹素衍生的 HSP40/J 结构域蛋白的新型抑制剂可消除突变型 p53

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

突变型p53抑制先天免疫信号传导，从而促进肿瘤发生

Comparative oncology approach to drug repurposing in osteosarcoma

骨肉瘤药物再利用的比较肿瘤学方法

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

DNAJA1 通过甲羟戊酸途径控制错误折叠突变 p53 的命运

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression

全基因组 RNAi 筛选确定 TMIGD3 同工酶 1 是 NF-κB 和骨肉瘤进展的抑制因子

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

突变型 p53 的等位基因特异性沉默可减弱显性负性和功能获得性活性

Targeting Oncogenic Mutant p53 for Cancer Therapy

针对致癌突变 p53 进行癌症治疗

Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways

凝血酶通过激活汇聚信号通路促进RPE细胞Ccnd1基因表达